Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Colesevelam on Insulin Sensitivity in Type 2 Diabetes
NCT00147745Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2005
- Primary completion
- Jan 2008
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of colesevelam in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Difference in Endogenous (Hepatic) Glucose Output During a High-dose Insulin Infusion at 12 weeks, Difference in Endogenous (Hepatic) Glucose Output During a Low-dose Insulin Infusion at 12 weeks and 1 more. Started Jun 2005; status: completed.
02
Drugs
colesevelam
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00147745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00147745.